PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1323204-6	1992	Treatment of platelets with inhibitors of PKC potentiates DAG mass formation in response to thrombin while prior activation of PKC with phorbol esters blocks DAG mass formation, consistent with PKC playing a negative feedback role, inhibiting inositol phospholipid breakdown.	Diglycerides	58-61	proline rich transmembrane protein 2	Homo sapiens	42-45	
1323204-6	1992	Treatment of platelets with inhibitors of PKC potentiates DAG mass formation in response to thrombin while prior activation of PKC with phorbol esters blocks DAG mass formation, consistent with PKC playing a negative feedback role, inhibiting inositol phospholipid breakdown.	Diglycerides	158-161	proline rich transmembrane protein 2	Homo sapiens	127-130	
1323204-6	1992	Treatment of platelets with inhibitors of PKC potentiates DAG mass formation in response to thrombin while prior activation of PKC with phorbol esters blocks DAG mass formation, consistent with PKC playing a negative feedback role, inhibiting inositol phospholipid breakdown.	Diglycerides	158-161	proline rich transmembrane protein 2	Homo sapiens	127-130	
1323204-9	1992	We have found that fibroblasts which overexpress the beta 1 isozyme of PKC display greatly enhanced DAG formation and phospholipase D activation in response to phorbol ester treatment.	Diglycerides	100-103	proline rich transmembrane protein 2	Homo sapiens	71-74